benzatropine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
atropine derivatives	333	86-13-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cogentin benztropine mesilate benzatropine benztropine tropine benzohydryl ether benztropine mesylate	A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine. Molecular weight: 307.44 Formula: C21H25NO CLOGP: 3.52 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 12.47 ALOGS: -5.41 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cogentin
benztropine mesilate
benzatropine
benztropine
tropine benzohydryl ether
benztropine mesylate

A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine.

Molecular weight: 307.44
Formula: C21H25NO
CLOGP: 3.52
LIPINSKI: 0
HAC: 2
HDO: 0
TPSA: 12.47
ALOGS: -5.41
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2	mg	O
2	mg	P

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.21 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Hosey CM, Chan R, Benet LZ
BA (Bioavailability)	29 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
March 5, 1954	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Granulocytopenia	337.77	17.60	95	8886	5178	46671903
Completed suicide	254.82	17.60	216	8765	145704	46531377
Tardive dyskinesia	164.97	17.60	60	8921	7483	46669598
Schizophrenia	157.52	17.60	60	8921	8508	46668573
Psychotic disorder	148.89	17.60	77	8904	22544	46654537
Neuroleptic malignant syndrome	116.19	17.60	52	8929	11070	46666011
Toxicity to various agents	110.25	17.60	167	8814	211599	46465482
Extrapyramidal disorder	109.22	17.60	50	8931	11218	46665863
Paranoia	105.79	17.60	48	8933	10549	46666532
Hallucination, auditory	101.96	17.60	47	8934	10709	46666372
Sedation	78.41	17.60	51	8930	22859	46654222
Dystonia	70.25	17.60	37	8944	11220	46665861
Muscle rigidity	65.76	17.60	34	8947	9927	46667154
Agitation	61.53	17.60	64	8917	55351	46621730
Blood prolactin increased	58.51	17.60	22	8959	3005	46674076
Catatonia	53.87	17.60	22	8959	3740	46673341
Schizoaffective disorder	53.14	17.60	17	8964	1435	46675646
Ileus paralytic	50.92	17.60	22	8959	4301	46672780
Clonus	48.83	17.60	21	8960	4059	46673022
Tremor	48.74	17.60	83	8898	115556	46561525
Suicidal ideation	46.89	17.60	56	8925	56326	46620755
Dyskinesia	46.52	17.60	41	8940	28884	46648197
Aggression	44.30	17.60	36	8945	22708	46654373
Hyperreflexia	43.74	17.60	21	8960	5233	46671848
Drooling	43.34	17.60	18	8963	3191	46673890
Oculogyric crisis	43.34	17.60	14	8967	1219	46675862
Akathisia	41.55	17.60	23	8958	7691	46669390
Myocarditis	41.48	17.60	23	8958	7716	46669365
Leukopenia	41.35	17.60	58	8923	68285	46608796
Delusion	40.97	17.60	26	8955	11162	46665919
Galactorrhoea	40.43	17.60	18	8963	3779	46673302
Salivary hypersecretion	36.88	17.60	20	8961	6425	46670656
Abnormal behaviour	36.18	17.60	31	8950	21027	46656054
Treatment noncompliance	36.00	17.60	36	8945	29695	46647386
Amaurosis	35.85	17.60	10	8971	526	46676555
Haemoglobin urine	33.03	17.60	7	8974	113	46676968
Confusional state	31.31	17.60	84	8897	159808	46517273
Hallucination	31.11	17.60	43	8938	49908	46627173
Mydriasis	30.12	17.60	21	8960	10532	46666549
Cardiac arrest	29.35	17.60	58	8923	90341	46586740
Parkinsonism	27.93	17.60	18	8963	7930	46669151
Torsade de pointes	27.46	17.60	21	8960	12133	46664948
Toxic encephalopathy	27.00	17.60	15	8966	5047	46672034
Amenorrhoea	26.08	17.60	18	8963	8877	46668204
Hyperprolactinaemia	25.26	17.60	12	8969	2920	46674161
Diabetes mellitus	25.22	17.60	39	8942	50026	46627055
Encephalitis autoimmune	24.78	17.60	9	8972	1115	46675966
Red blood cells urine	24.06	17.60	7	8974	429	46676652
Lipids decreased	24.00	17.60	4	8977	15	46677066
Arthralgia	23.95	17.60	21	8960	364582	46312499
Eosinophil count abnormal	23.52	17.60	7	8974	464	46676617
Weight increased	23.24	17.60	77	8904	164396	46512685
Electrocardiogram QT prolonged	23.13	17.60	38	8943	51287	46625794
Dysarthria	22.92	17.60	32	8949	37466	46639615
Suspected suicide	22.67	17.60	13	8968	4648	46672433
Schizoaffective disorder bipolar type	22.08	17.60	5	8976	111	46676970
Joint swelling	21.90	17.60	3	8978	166070	46511011
Cognitive disorder	21.84	17.60	31	8950	36852	46640229
Facial paralysis	21.73	17.60	19	8962	13231	46663850
Diarrhoea	21.08	17.60	48	8933	559554	46117527
Mania	20.76	17.60	17	8964	10829	46666252
Restlessness	20.62	17.60	25	8956	25499	46651582
Cardio-respiratory arrest	20.13	17.60	39	8942	59830	46617251
Mental disorder	19.83	17.60	23	8958	22402	46654679
Bipolar disorder	19.82	17.60	14	8967	7163	46669918
Areflexia	19.03	17.60	10	8971	3013	46674068
Device leakage	18.48	17.60	12	8969	5353	46671728
Metabolic disorder	17.99	17.60	11	8970	4421	46672660

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Granulocytopenia	532.51	17.68	161	10493	6065	29935759
Completed suicide	198.99	17.68	209	10445	99283	29842541
Neuroleptic malignant syndrome	168.49	17.68	92	10562	16203	29925621
Tardive dyskinesia	152.39	17.68	60	10594	4997	29936827
Myocarditis	148.26	17.68	72	10582	9939	29931885
Psychotic disorder	147.27	17.68	93	10561	21422	29920402
Extrapyramidal disorder	134.98	17.68	69	10585	10624	29931200
Schizophrenia	124.79	17.68	62	10592	8986	29932838
Toxicity to various agents	120.49	17.68	221	10433	176962	29764862
Agitation	97.96	17.68	108	10546	53965	29887859
Hallucination, auditory	92.18	17.68	52	10602	9737	29932087
Dystonia	84.44	17.68	49	10605	9678	29932146
Akathisia	77.11	17.68	39	10615	5865	29935959
Drooling	71.15	17.68	30	10624	2975	29938849
Tremor	69.61	17.68	108	10546	75255	29866569
Device leakage	62.08	17.68	29	10625	3665	29938159
Galactorrhoea	61.61	17.68	16	10638	339	29941485
Sedation	61.28	17.68	49	10605	16324	29925500
Hyperprolactinaemia	61.26	17.68	21	10633	1179	29940645
Leukopenia	61.20	17.68	87	10567	56072	29885752
Syringe issue	56.05	17.68	25	10629	2840	29938984
Paranoia	54.98	17.68	38	10616	10150	29931674
Abnormal behaviour	54.89	17.68	56	10598	25567	29916257
Muscle rigidity	54.74	17.68	38	10616	10223	29931601
Schizoaffective disorder	51.98	17.68	18	10636	1042	29940782
Treatment noncompliance	51.94	17.68	54	10600	25199	29916625
Product dose omission issue	49.50	17.68	104	10550	91527	29850297
Drug abuse	47.68	17.68	96	10558	81976	29859848
Aggression	47.49	17.68	62	10592	36845	29904979
Dystonic tremor	44.45	17.68	10	10644	112	29941712
Priapism	44.11	17.68	25	10629	4718	29937106
Inappropriate schedule of product administration	43.92	17.68	62	10592	39666	29902158
Antipsychotic drug level increased	41.59	17.68	21	10633	3145	29938679
Catatonia	40.50	17.68	23	10631	4357	29937467
Cogwheel rigidity	39.63	17.68	15	10639	1121	29940703
Drug interaction	38.96	17.68	157	10497	199411	29742413
Parkinsonism	38.95	17.68	27	10627	7242	29934582
Restlessness	37.21	17.68	43	10611	22556	29919268
Mental status changes	35.39	17.68	54	10600	37025	29904799
Delusion	34.79	17.68	31	10623	11958	29929866
Drug level increased	33.76	17.68	37	10617	18317	29923507
Dyskinesia	33.38	17.68	40	10614	21794	29920030
Agranulocytosis	33.22	17.68	40	10614	21902	29919922
Anticholinergic syndrome	32.85	17.68	12	10642	812	29941012
Suicidal ideation	32.23	17.68	51	10603	36063	29905761
Blood prolactin increased	29.72	17.68	13	10641	1409	29940415
Lethargy	28.85	17.68	51	10603	39468	29902356
Eosinophilic pleural effusion	28.82	17.68	8	10646	220	29941604
Homicidal ideation	28.49	17.68	15	10639	2448	29939376
Needle issue	27.27	17.68	17	10637	3815	29938009
Mania	27.22	17.68	24	10630	9130	29932694
Oculogyric crisis	26.90	17.68	12	10642	1363	29940461
Weight increased	26.31	17.68	72	10582	74841	29866983
Musculoskeletal stiffness	25.79	17.68	46	10608	35835	29905989
Device malfunction	25.60	17.68	22	10632	8089	29933735
Blood triglycerides increased	25.33	17.68	28	10626	13989	29927835
Antipsychotic drug level decreased	25.09	17.68	10	10644	858	29940966
Febrile neutropenia	25.01	17.68	4	10650	106689	29835135
Bipolar disorder	25.00	17.68	16	10638	3760	29938064
Overdose	24.75	17.68	76	10578	84261	29857563
Sinus tachycardia	24.68	17.68	29	10625	15475	29926349
Delirium	24.12	17.68	48	10606	40583	29901241
Diarrhoea	24.07	17.68	52	10602	334051	29607773
Haemophagocytic lymphohistiocytosis	23.92	17.68	23	10631	9768	29932056
Type 2 diabetes mellitus	22.55	17.68	26	10628	13596	29928228
Blood creatine phosphokinase increased	21.61	17.68	48	10606	43800	29898024
Gynaecomastia	21.13	17.68	20	10634	8331	29933493
Blood pH decreased	21.08	17.68	12	10642	2283	29939541
Salivary hypersecretion	20.84	17.68	19	10635	7547	29934277
Globulins decreased	20.48	17.68	6	10648	201	29941623
Disease progression	18.70	17.68	3	10651	79871	29861953
Psychiatric decompensation	18.09	17.68	9	10645	1306	29940518

Pharmacologic Action:

Source	Code	Description
ATC	N04AC01	NERVOUS SYSTEM ANTI-PARKINSON DRUGS ANTICHOLINERGIC AGENTS Ethers of tropine or tropine derivatives
FDA MoA	N0000000207	Histamine Receptor Antagonists
FDA MoA	N0000175370	Cholinergic Antagonists
FDA EPC	N0000175574	Anticholinergic
FDA EPC	N0000175750	Antihistamine
CHEBI has role	CHEBI:48407	antiparkinson agent
CHEBI has role	CHEBI:48876	antimuskarinika
CHEBI has role	CHEBI:50370	parasympatholytics
CHEBI has role	CHEBI:66956	antidyskinetic drugs
CHEBI has role	CHEBI:146270	oneirogens
CHEBI has role	CHEBI:149553	anti-coronaviral agents
MeSH PA	D018726	Anti-Dyskinesia Agents
MeSH PA	D000978	Antiparkinson Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018765	Dopamine Uptake Inhibitors
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018727	Muscarinic Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D010276	Parasympatholytics
MeSH PA	D018373	Peripheral Nervous System Agents

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Postencephalitic parkinsonism	indication	19972008	DOID:14332
Parkinsonism	indication	32798002
Parkinson's disease	indication	49049000	DOID:14330
Extrapyramidal disease	indication	76349003
Arteriosclerotic Parkinsonism	indication
Urinary tract obstruction	contraindication	7163005	DOID:5200
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Severe chronic ulcerative colitis	contraindication	14311001
Disorder of autonomic nervous system	contraindication	15241006
Toxic megacolon	contraindication	28536002	DOID:1770
Atony of colon	contraindication	29479008
Shigellosis	contraindication	36188001
Hypertensive disorder	contraindication	38341003	DOID:10763
Conduction disorder of the heart	contraindication	44808001
Low blood pressure	contraindication	45007003
Achalasia of esophagus	contraindication	45564002	DOID:9164
Chronic heart failure	contraindication	48447003
Dysuria	contraindication	49650001
Paralytic ileus	contraindication	55525008	DOID:8442
Ulcerative colitis	contraindication	64766004	DOID:8577
Hiatal hernia	contraindication	84089009	DOID:12642
Open-angle glaucoma	contraindication	84494001	DOID:1067
Kidney disease	contraindication	90708001	DOID:557
Thyrotoxicosis	contraindication	90739004	DOID:7997
Myasthenia gravis	contraindication	91637004	DOID:437
Tardive dyskinesia	contraindication	102449007
Dysentery	contraindication	111939009
Gastrointestinal obstruction	contraindication	126765001
Bleeding	contraindication	131148009
Gastroesophageal reflux disease	contraindication	235595009	DOID:8534
Disease of liver	contraindication	235856003	DOID:409
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Fever	contraindication	386661006
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Pseudomembranous enterocolitis	contraindication	397683000
Gastric ulcer	contraindication	397825006	DOID:10808
Disorder of coronary artery	contraindication	414024009

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.86	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN	ANTAGONIST	Ki	9.64	WOMBAT-PK	CHEMBL
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN	ANTAGONIST	Ki	8.55	WOMBAT-PK
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN	ANTAGONIST	Ki	8.96	WOMBAT-PK
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN	ANTAGONIST	Ki	8.96	WOMBAT-PK
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN	ANTAGONIST	Ki	8.85	WOMBAT-PK
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.69	DRUG MATRIX
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	7.23	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.86	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	8.16	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	6.90	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	7.49	DRUG MATRIX
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	5.89	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	7.52	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.65	DRUG MATRIX
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	5.93	DRUG MATRIX
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	7.24	DRUG MATRIX
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	7.59	DRUG MATRIX
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		IC50	4.62	CHEMBL
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	8.96	WOMBAT-PK
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Kd	7.25	WOMBAT-PK
Sodium-dependent neutral amino acid transporter B(0)AT1	Unclassified	Q695T7	S6A19_HUMAN	INHIBITOR	IC50	4.36	IUPHAR
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	7.39	DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	6.95	DRUG MATRIX
Sodium-dependent serotonin transporter	Transporter		SC6A4_RAT		Ki	5.29	CHEMBL
Sodium-dependent dopamine transporter	Transporter		SC6A3_RAT		Ki	6.93	CHEMBL
Muscarinic acetylcholine receptor M1	GPCR		ACM1_RAT		Ki	9.23	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR		ACM2_RAT		Ki	8.59	CHEMBL
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	6.85	CHEMBL

External reference:

ID	Source
1NHL2J4X8K	UNII
D00778	KEGG_DRUG
132-17-2	SECONDARY_CAS_RN
4017824	VANDF
4019630	VANDF
C0005098	UMLSCUI
CHEBI:3048	CHEBI
CXQ	PDB_CHEM_ID
CHEMBL1201203	ChEMBL_ID
CHEMBL1200383	ChEMBL_ID
DB00245	DRUGBANK_ID
D001590	MESH_DESCRIPTOR_UI
292	INN_ID
1201549	PUBCHEM_CID
7601	IUPHAR_LIGAND_ID
1424	RXNORM
3130	MMSL
4264	MMSL
563	MMSL
d00175	MMSL
001647	NDDF
004667	NDDF
29527005	SNOMEDCT_US
372846002	SNOMEDCT_US
77390008	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9729	INJECTION	1 mg	INTRAMUSCULAR	ANDA	14 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2437	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2438	TABLET	1 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0603-2439	TABLET	2 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8210	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8211	TABLET	1 mg	ORAL	ANDA	16 sections
benztropine mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8352	TABLET	2 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1080	TABLET	0.50 mg	ORAL	ANDA	15 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1081	TABLET	1 mg	ORAL	ANDA	15 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1082	TABLET	2 mg	ORAL	ANDA	15 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6788	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6789	TABLET	2 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6790	TABLET	1 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	10135-606	TABLET	0.50 mg	ORAL	ANDA	15 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	10135-607	TABLET	1 mg	ORAL	ANDA	15 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	10135-608	TABLET	2 mg	ORAL	ANDA	15 sections
benztropine mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	10858-011	INJECTION	1 mg	INTRAMUSCULAR	ANDA	1 sections
Benztropine Mesylate Injection, USP	HUMAN PRESCRIPTION DRUG LABEL	1	14789-300	INJECTION	1 mg	PARENTERAL	ANDA	11 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	17478-012	INJECTION	1 mg	INTRAVENOUS	NDA authorized generic	16 sections
BENZTROPINE MESYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-286	TABLET	2 mg	ORAL	ANDA	15 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	31722-218	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	31722-219	TABLET	1 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	31722-220	TABLET	2 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	43353-580	TABLET	1 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	43353-707	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	43353-796	TABLET	1 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	43353-913	TABLET	0.50 mg	ORAL	ANDA	16 sections
Benztropine Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3116	TABLET	1 mg	ORAL	ANDA	15 sections
BENZTROPINE MESYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3882	TABLET	2 mg	ORAL	ANDA	13 sections
BENZTROPINE MESYLATE	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3883	TABLET	2 mg	ORAL	ANDA	13 sections